On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma

•Approximately 30–40% of patients with NSCLC have a KRAS mutation.•New targeted therapies for patients with KRAS-mutant NSCLC are emerging.•Sotorasib was approved by the FDA in May 2021.•Adagrasib received Breakthrough Therapy Designation by the FDA in June 2021.•Strong rationale exists for combinin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2021-10, Vol.160, p.152-165
Hauptverfasser: Lindsay, Colin R., Garassino, Marina C., Nadal, Ernest, Öhrling, Katarina, Scheffler, Matthias, Mazières, Julien
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 165
container_issue
container_start_page 152
container_title Lung cancer (Amsterdam, Netherlands)
container_volume 160
creator Lindsay, Colin R.
Garassino, Marina C.
Nadal, Ernest
Öhrling, Katarina
Scheffler, Matthias
Mazières, Julien
description •Approximately 30–40% of patients with NSCLC have a KRAS mutation.•New targeted therapies for patients with KRAS-mutant NSCLC are emerging.•Sotorasib was approved by the FDA in May 2021.•Adagrasib received Breakthrough Therapy Designation by the FDA in June 2021.•Strong rationale exists for combining direct anti-KRAS agents with other treatments. Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered ‘undruggable’, several novel direct KRASG12C inhibitors have shown encouraging signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by the US Food and Drug Administration. This review examines the role of KRAS mutations in NSCLC and the challenges in targeting KRAS. Based on specific KRAS biology, it reports exciting progress, exploring the use of novel direct KRAS inhibitors as monotherapy or in combination with other targeted therapies, chemotherapy, and immunotherapy.
doi_str_mv 10.1016/j.lungcan.2021.07.005
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2563423262</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500221004748</els_id><sourcerecordid>2563423262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-da40114c4c212750927bfca0a39afb849ed88c0ab169d0e4904b246e25827513</originalsourceid><addsrcrecordid>eNqFkE9LxDAQxYMouK5-BCFHL62TtN22XkTEfygI6j1O06lmaZM1yQp-e1PWu5eZw_ze8N5j7FRALkCsztf5uLUfGm0uQYoc6hyg2mML0dQya4pC7rNF4tqsApCH7CiENYCoBbQL9v5seUT_QfGCv2A0zuLIcbPxDvUnBR4df3y5euXGfprOzHc-OM-jJ4wT2cjdwK2zWZhwHLmmNGYzXKPXxroJj9nBgGOgk7-9ZG-3N2_X99nT893D9dVTpoumjVmPJQhR6lJLIesKWll3g0bAosWha8qW-qbRgF3K0QOVLZSdLFckqybholiys93b5PxrSyGqyYTZDlpy26BktSpKWciVTGi1Q7V3IXga1MabCf2PEqDmQtVa_RWq5kIV1CoVmnSXOx2lGN-GvArakNXUG086qt6Zfz78AuXtgV4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2563423262</pqid></control><display><type>article</type><title>On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma</title><source>Access via ScienceDirect (Elsevier)</source><creator>Lindsay, Colin R. ; Garassino, Marina C. ; Nadal, Ernest ; Öhrling, Katarina ; Scheffler, Matthias ; Mazières, Julien</creator><creatorcontrib>Lindsay, Colin R. ; Garassino, Marina C. ; Nadal, Ernest ; Öhrling, Katarina ; Scheffler, Matthias ; Mazières, Julien</creatorcontrib><description>•Approximately 30–40% of patients with NSCLC have a KRAS mutation.•New targeted therapies for patients with KRAS-mutant NSCLC are emerging.•Sotorasib was approved by the FDA in May 2021.•Adagrasib received Breakthrough Therapy Designation by the FDA in June 2021.•Strong rationale exists for combining direct anti-KRAS agents with other treatments. Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered ‘undruggable’, several novel direct KRASG12C inhibitors have shown encouraging signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by the US Food and Drug Administration. This review examines the role of KRAS mutations in NSCLC and the challenges in targeting KRAS. Based on specific KRAS biology, it reports exciting progress, exploring the use of novel direct KRAS inhibitors as monotherapy or in combination with other targeted therapies, chemotherapy, and immunotherapy.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2021.07.005</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>G12C ; Immunotherapy ; Lung cancer ; Oncogene ; Targeted therapy</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2021-10, Vol.160, p.152-165</ispartof><rights>2021 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-da40114c4c212750927bfca0a39afb849ed88c0ab169d0e4904b246e25827513</citedby><cites>FETCH-LOGICAL-c389t-da40114c4c212750927bfca0a39afb849ed88c0ab169d0e4904b246e25827513</cites><orcidid>0000-0002-9031-1368</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lungcan.2021.07.005$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Lindsay, Colin R.</creatorcontrib><creatorcontrib>Garassino, Marina C.</creatorcontrib><creatorcontrib>Nadal, Ernest</creatorcontrib><creatorcontrib>Öhrling, Katarina</creatorcontrib><creatorcontrib>Scheffler, Matthias</creatorcontrib><creatorcontrib>Mazières, Julien</creatorcontrib><title>On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma</title><title>Lung cancer (Amsterdam, Netherlands)</title><description>•Approximately 30–40% of patients with NSCLC have a KRAS mutation.•New targeted therapies for patients with KRAS-mutant NSCLC are emerging.•Sotorasib was approved by the FDA in May 2021.•Adagrasib received Breakthrough Therapy Designation by the FDA in June 2021.•Strong rationale exists for combining direct anti-KRAS agents with other treatments. Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered ‘undruggable’, several novel direct KRASG12C inhibitors have shown encouraging signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by the US Food and Drug Administration. This review examines the role of KRAS mutations in NSCLC and the challenges in targeting KRAS. Based on specific KRAS biology, it reports exciting progress, exploring the use of novel direct KRAS inhibitors as monotherapy or in combination with other targeted therapies, chemotherapy, and immunotherapy.</description><subject>G12C</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Oncogene</subject><subject>Targeted therapy</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkE9LxDAQxYMouK5-BCFHL62TtN22XkTEfygI6j1O06lmaZM1yQp-e1PWu5eZw_ze8N5j7FRALkCsztf5uLUfGm0uQYoc6hyg2mML0dQya4pC7rNF4tqsApCH7CiENYCoBbQL9v5seUT_QfGCv2A0zuLIcbPxDvUnBR4df3y5euXGfprOzHc-OM-jJ4wT2cjdwK2zWZhwHLmmNGYzXKPXxroJj9nBgGOgk7-9ZG-3N2_X99nT893D9dVTpoumjVmPJQhR6lJLIesKWll3g0bAosWha8qW-qbRgF3K0QOVLZSdLFckqybholiys93b5PxrSyGqyYTZDlpy26BktSpKWciVTGi1Q7V3IXga1MabCf2PEqDmQtVa_RWq5kIV1CoVmnSXOx2lGN-GvArakNXUG086qt6Zfz78AuXtgV4</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Lindsay, Colin R.</creator><creator>Garassino, Marina C.</creator><creator>Nadal, Ernest</creator><creator>Öhrling, Katarina</creator><creator>Scheffler, Matthias</creator><creator>Mazières, Julien</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9031-1368</orcidid></search><sort><creationdate>202110</creationdate><title>On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma</title><author>Lindsay, Colin R. ; Garassino, Marina C. ; Nadal, Ernest ; Öhrling, Katarina ; Scheffler, Matthias ; Mazières, Julien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-da40114c4c212750927bfca0a39afb849ed88c0ab169d0e4904b246e25827513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>G12C</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Oncogene</topic><topic>Targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lindsay, Colin R.</creatorcontrib><creatorcontrib>Garassino, Marina C.</creatorcontrib><creatorcontrib>Nadal, Ernest</creatorcontrib><creatorcontrib>Öhrling, Katarina</creatorcontrib><creatorcontrib>Scheffler, Matthias</creatorcontrib><creatorcontrib>Mazières, Julien</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lindsay, Colin R.</au><au>Garassino, Marina C.</au><au>Nadal, Ernest</au><au>Öhrling, Katarina</au><au>Scheffler, Matthias</au><au>Mazières, Julien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><date>2021-10</date><risdate>2021</risdate><volume>160</volume><spage>152</spage><epage>165</epage><pages>152-165</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><abstract>•Approximately 30–40% of patients with NSCLC have a KRAS mutation.•New targeted therapies for patients with KRAS-mutant NSCLC are emerging.•Sotorasib was approved by the FDA in May 2021.•Adagrasib received Breakthrough Therapy Designation by the FDA in June 2021.•Strong rationale exists for combining direct anti-KRAS agents with other treatments. Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered ‘undruggable’, several novel direct KRASG12C inhibitors have shown encouraging signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by the US Food and Drug Administration. This review examines the role of KRAS mutations in NSCLC and the challenges in targeting KRAS. Based on specific KRAS biology, it reports exciting progress, exploring the use of novel direct KRAS inhibitors as monotherapy or in combination with other targeted therapies, chemotherapy, and immunotherapy.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.lungcan.2021.07.005</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-9031-1368</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0169-5002
ispartof Lung cancer (Amsterdam, Netherlands), 2021-10, Vol.160, p.152-165
issn 0169-5002
1872-8332
language eng
recordid cdi_proquest_miscellaneous_2563423262
source Access via ScienceDirect (Elsevier)
subjects G12C
Immunotherapy
Lung cancer
Oncogene
Targeted therapy
title On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A51%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=On%20target:%20Rational%20approaches%20to%20KRAS%20inhibition%20for%20treatment%20of%20non-small%20cell%20lung%20carcinoma&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Lindsay,%20Colin%20R.&rft.date=2021-10&rft.volume=160&rft.spage=152&rft.epage=165&rft.pages=152-165&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2021.07.005&rft_dat=%3Cproquest_cross%3E2563423262%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2563423262&rft_id=info:pmid/&rft_els_id=S0169500221004748&rfr_iscdi=true